All AbMole products are for research use only, cannot be used for human consumption.
Tasosartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Tasosartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors. Antagonism of the AT1 receptor with tasosartan reduces blood pressure at rest and during submaximal exercise but not during maximal exercise. The reduced blood pressure was associated with a reduced total peripheral resistance during submaximal exercise but not at rest in the control condition while cardiac output was unaltered in either condition. Lastly, tasosartan did not impair working capacity as measured from peak workload and oxygen uptake.
 |
Source | J Pharmacol Exp Ther (2000). Figure 4. Tasosartan |
| Method | receptor binding assay | |
| Cell Lines | vascular smooth muscle cell | |
| Concentrations | ||
| Incubation Time | 4 to 6 h | |
| Results | In the receptor binding assay, the addition of 6.25% human plasma to the buffer (final concentration of plasma protein 0.4%) resulted in small but significant differences in the affinity of tasosartan for the AT1 receptor (IC50 shifted from 2.0 to 9.5 nM), whereas the same procedure shifted IC50 for enoltasosartan from 0.4 to 340 nM |
 |
Source | J Pharmacol Exp Ther (2000). Figure 2. Tasosartan |
| Method | oral administration | |
| Cell Lines | ||
| Concentrations | 50 mg | |
| Incubation Time | 8.0 h | |
| Results | Tasosartan was rapidly absorbed after oral administration and Tmax 30 min (with Cmax of 1596 ± 250 ng/ml) was observed in all subjects (n=12). |
| Cell Experiment | |
|---|---|
| Cell lines | |
| Preparation method | |
| Concentrations | |
| Incubation time | |
| Animal Experiment | |
|---|---|
| Animal models | mice |
| Formulation | |
| Dosages | 50 mg/kg |
| Administration | p.o. or i.v. |
| Molecular Weight | 411.46 |
| Formula | C23H21N7O |
| CAS Number | 145733-36-4 |
| Solubility (25°C) | DMSO 10 mM |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[3] Dina R, et al. Am J Health Syst Pharm. Angiotensin II-receptor antagonists: an overview.
| Related Angiotensin Receptor Products |
|---|
| TRV055 hydrochloride
TRV055 hydrochloride, a G-protein-biased agonist, is a Gq-biased ligand of the angiotensin II receptor type 1 (AT1R). TRV055 hydrochloride is efficacious in stimulating cellular Gq-mediated signaling. |
| (Sar1, Ile4, 8)-Angiotensin II
(Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. |
| TRV055
TRV055, a G-protein-biased agonist, is a Gq-biased ligand of the angiotensin II receptor type 1 (AT1R). |
| Alamandine
Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. |
| (Sar1)-Angiotensin II
(Sar1)-Angiotensin II, an analogue of Angiotensin II, is a specific agonist of angiotensin AT1 receptor. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
